Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12368443 | 0.82 | LMNA (0.39) | LMNAADORA3KMT2ALIPE | |
| SCHEMBL10049703 | 0.75 | KDM4E (0.32) | KMT2A | |
| SCHEMBL14803801 | 0.73 | LMNA (0.43) | LMNAADORA3KMT2A | |
| SCHEMBL10093812 | 0.70 | LMNA (0.31) | LMNAADORA3 | |
| SCHEMBL8330118 | 0.68 | — | — | |
| SCHEMBL22017085 | 0.67 | KDM4E (0.46) | LMNAADORA3KMT2A | |
| SCHEMBL21957413 | 0.67 | NOX4 (0.31) | — | |
| SCHEMBL25447398 | 0.67 | — | — | |
| SCHEMBL25003705 | 0.66 | ADORA3 (0.49) | LMNAADORA3 | |
| SCHEMBL12611135 | 0.65 | LMNA (0.35) | LMNAADORA3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | LMNA 2900/4885ADORA3 1752/4885KMT2A 2755/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | LMNA 2900/4885ADORA3 1752/4885KMT2A 2755/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | LMNA 2991/4885ADORA3 1388/4885KMT2A 2981/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | LMNA 2900/4885ADORA3 1752/4885KMT2A 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.